Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Qyuns Therapeutics
company
About
Qyuns Therapeutics develops monoclonal antibody drugs for autoimmune diseases.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- ¥100M
- Industries
- Health Care,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥100M $20M
Qyuns Therapeutics has raised a total of
¥100M $20M
in funding over 2 rounds. Their latest funding was raised on
Mar 7, 2022 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 7, 2022 | Series C | ¥100M | 1 | — | — | Detail |
| May 7, 2020 | Series B | — | 1 | — | — | Detail |
| Jul 31, 2019 | Series B | $20M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Qyuns Therapeutics is funded by 3 investors.
Shenzhen Kaiding Juncan venture Cci Capital
and Jiayin Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series B |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
